Heron Therapeutics Statistics
Want to see HRTX full AI Analyst Report?
Heron Therapeutics (HRTX) Stock Statistics & Valuation Metrics
Total Valuation
Heron Therapeutics has a market cap or net worth of $51.94M. The enterprise value is $169.18M.
- Market Cap
- $51.94M
- Enterprise Value
- $169.18M
Share Statistics
Heron Therapeutics has 190,273,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 190,273,590
- Owned by Insiders
- 5.70%
- Owned by Institutions
- 57.78%
Financial Efficiency
Heron Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -1.59%.
- Return on Equity (ROE)
- -1.41
- Return on Assets (ROA)
- -0.08
- Return on Invested Capital (ROIC)
- -1.59%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 1.21M
- Profits Per Employee
- -157.77K
- Employee Count
- 128
- Asset Turnover
- 0.61
- Inventory Turnover
- 0.45
Valuation Ratios
The current PE Ratio of Heron Therapeutics is -2.33. Heron Therapeutics’s PEG ratio is 0.03.
- PE Ratio
- -2.33
- PS Ratio
- 0.34
- PB Ratio
- 10.26
- Price to FCF
- -3.50
- Price to Operating Cash Flow
- -3.67
- PEG Ratio
- 0.03
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 154.90M and earned -20.20M in profits. Earnings per share was -0.12.
- Revenue
- 154.90M
- Gross Profit
- 113.56M
- Operating Income
- -2.54M
- Pretax Income
- -20.20M
- Net Income
- -20.20M
- EBITDA
- -17.88M
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was -13.73M and capital expenditures -631,000, giving a free cash flow of -14.36M billion.
- Operating Cash Flow
- -13.73M
- Free Cash Flow
- -14.36M
- Free Cash Flow per Share
- -0.08
Dividends & Yields
Heron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -28.28%
- Earnings Yield
- -42.31%
Stock Price Statistics
- Beta
- 1.49
- 52-Week Price Change
- -75.78%
- 50-Day Moving Average
- 0.32
- 200-Day Moving Average
- 0.62
- Relative Strength Index (RSI)
- 38.63
- Average Volume (3m)
- 4.55M
Important Dates
Heron Therapeutics upcoming earnings date is Mar 04, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 09, 2026
- Next Earnings Date
- Mar 04, 2027
- Ex-Dividend Date
- ―
Financial Position
Heron Therapeutics as a current ratio of 2.48, with Debt / Equity ratio of 981.22%
- Current Ratio
- 2.48
- Quick Ratio
- 1.51
- Debt to Market Cap
- 0.65
- Net Debt to EBITDA
- -6.26
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Heron Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Heron Therapeutics EV to EBITDA ratio is -11.16, with an EV/FCF ratio of -11.90.
- EV to Sales
- 1.15
- EV to EBITDA
- -11.16
- EV to Free Cash Flow
- -11.90
- EV to Operating Cash Flow
- -12.45
Balance Sheet
Heron Therapeutics has $23.45M in cash and marketable securities with $131.73M in debt, giving a net cash position of -$108.28M billion.
- Cash & Marketable Securities
- $23.45M
- Total Debt
- $131.73M
- Net Cash
- -$108.28M
- Net Cash Per Share
- -$0.57
- Tangible Book Value Per Share
- $0.03
Margins
Gross margin is 73.81%, with operating margin of -5.69%, and net profit margin of -14.55%.
- Gross Margin
- 73.81%
- Operating Margin
- -5.69%
- Pretax Margin
- -14.55%
- Net Profit Margin
- -14.55%
- EBITDA Margin
- -10.33%
- EBIT Margin
- -11.62%
Analyst Forecast
The average price target for Heron Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 1
- Revenue Growth Forecast
- -4.44%
- EPS Growth Forecast
- -47.21%
Scores
- Smart Score
- 2
- AI Score
- 43

